Glenmark, InvaGen ink deal to develop 7 products

Glenmark Pharmaceuticals has signed a collaboration agreement with InvaGen Pharmaceuticals Inc (InvaGen) for joint development, filing and marketing of seven generic products in the US.

According to a release issued by Glenmark Pharmaceuticals to the BSE today, the products listed in the agreement include a mixture of off-patent and patent-protected molecules with cumulative annual sales in the US of about $4.1 billion.

As per the agreement, InvaGen will undertake filing of the abbreviated new drug applications (ANDAs) while Glenmark Pharmaceuticals will be responsible for obtaining regulatory approval, the release added.

"Upon approval, the company's US subsidiary, Glenmark Pharmaceuticals Inc, will exclusively market the products while InvaGen will be responsible for their manufacture and supply. All development and regulatory costs and profits on sale in the US will be shared equally between the company and InvaGen. Of the list, one ANDA has already been filed till date and three more are expected to be filed by March 2006," the release said.
Glenmark has also signed a collaboration agreement with Shasun Chemicals and Drugs for joint development and marketing of 13 generic products in the US.

Glenn Saldanha, managing director and CEO of Glenmark Pharmaceuticals, said: "We are happy to take our association with InvaGen even further. The deal is also in line with our multi-pronged approach to strengthen the presence as a serious generics player in US market."